Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2016

01-06-2016 | Clinical

Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management

Authors: Kosei Nakajima, Dong Hyo Kho, Takashi Yanagawa, Melissa Zimel, Elisabeth Heath, Victor Hogan, Avraham Raz

Published in: Cancer and Metastasis Reviews | Issue 2/2016

Login to get access

Abstract

The skeleton is frequently a secondary growth site of disseminated cancers, often leading to painful and devastating clinical outcomes. Metastatic cancer distorts bone marrow homeostasis through tumor-derived factors, which shapes different bone tumor microenvironments depending on the tumor cells’ origin. Here, we propose a novel insight on tumor-secreted Galectin-3 (Gal-3) that controls the induction of an inflammatory cascade, differentiation of osteoblasts, osteoclasts, and bone marrow cells, resulting in bone destruction and therapeutic failure. In the approaching era of personalized medicine, the current treatment modalities targeting bone metastatic environments are provided to the patient with limited consideration of the cancer cells’ origin. Our new outlook suggests delivering individual tumor microenvironment treatments based on the expression level/activity/functionality of tumor-derived factors, rather than utilizing a commonly shared therapeutic umbrella. The notion of “Gal-3-associated bone remodeling” could be the first step toward a specific personalized therapy for each cancer type generating a different bone niche in patients afflicted with non-curable bone metastasis.
Literature
1.
Raz, A., Bucana, C., McLellan, W., & Fidler, I. J. (1980). Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential. Nature, 284(5754), 363–364.PubMedCrossRef
2.
Raz, A., & Lotan, R. (1981). Lectin-like activities associated with human and murine neoplastic cells. Cancer Research, 41(9 Pt 1), 3642–3647.PubMed
3.
Liu, F. T., & Rabinovich, G. A. (2005). Galectins as modulators of tumour progression. Nature Review. Cancer, 5(1), 29–41.CrossRef
4.
5.
6.
Lakshminarayan, R., Wunder, C., Becken, U., Howes, M. T., Benzing, C., Arumugam, S., et al. (2014). Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nature Cell Biology, 16(6), 595–606.PubMedCrossRef
7.
Long, F. (2012). Building strong bones: molecular regulation of the osteoblast lineage. Nature Reviews. Molecular Cell Biology, 13(1), 27–38.CrossRef
8.
Nakajima, K., Kho, D. H., Yanagawa, T., Harazono, Y., Gao, X., Hogan, V., et al. (2014). Galectin-3 inhibits osteoblast differentiation through notch signaling. Neoplasia, 16(11), 939–949.PubMedPubMedCentralCrossRef
9.
Stock, M., Schäfer, H., Stricker, S., Gross, G., Mundlos, S., & Otto, F. (2003). Expression of galectin-3 in skeletal tissues is controlled by Runx2. The Journal of Biological Chemistry, 278(19), 17360–17367.PubMedCrossRef
10.
Brand, C., Oliveira, F. L., Ricon, L., Fermino, M. L., Boldrini, L. C., Hsu, D. K., et al. (2011). The bone marrow compartment is modified in the absence of galectin-3. Cell and Tissue Research, 346(3), 427–437.PubMedPubMedCentralCrossRef
11.
Edwards, J. R., & Mundy, G. R. (2011). Advances in osteoclast biology: old findings and new insights from mouse models. Nature Reviews. Rheumatology, 7(4), 235–243.PubMedCrossRef
12.
Niida, S., Amizuka, N., Hara, F., Ozawa, H., & Kodama, H. (1994). Expression of Mac-2 antigen in the preosteoclast and osteoclast identified in the op/op mouse injected with macrophage colony-stimulating factor. Journal of Bone and Mineral Research, 9(6), 873–881.PubMedCrossRef
13.
Nakajima, K., Kho, D. H., Yanagawa, T., Harazono, Y., Hogan, V., Chen, W., et al. (2016). Galectin-3 cleavage alters bone remodeling: different outcomes in breast and prostate cancer skeletal metastasis. Cancer Research, 76(6), 1391–1402.
14.
Leenen, P. J., Jansen, A. M., & van Ewijk, W. (1986). Murine macrophage cell lines can be ordered in a linear differentiation sequence. Differentiation, 32(2), 157–164.PubMedCrossRef
15.
Crotti, T. N., Dharmapatni, A. A., Alias, E., & Haynes, D. R. (2015). Osteoimmunology: major and costimulatory pathway expression associated with chronic inflammatory induced bone loss. Journal of Immunology Research, 2015(2015), 281287.PubMedPubMedCentral
16.
Takayanagi, H. (2009). Osteoimmunology and the effects of the immune system on bone. Nature Reviews. Rheumatology, 5(12), 667–676.PubMedCrossRef
17.
Kong, Y. Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., & Morony, S. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402(6759), 304–309.
18.
Forsman, H., Islander, U., Andréasson, E., Andersson, A., Onnheim, K., Karlström, A., et al. (2011). Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis and Rheumatism, 63(2), 445–454.PubMedCrossRef
19.
20.
Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2006). New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology, 18(4), 396–404.PubMedCrossRef
21.
Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298–1312.PubMedPubMedCentralCrossRef
22.
Joseph, J., Shiozawa, Y., Jung, Y., Kim, J. K., Pedersen, E., Mishra, A., et al. (2012). Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Molecular Cancer Research, 10(3), 282–292.PubMedPubMedCentralCrossRef
23.
Krugluger, W., Frigeri, L. G., Lucas, T., Schmer, M., Förster, O., Liu, F. T., et al. (1997). Galectin-3 inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven rat bone marrow cell proliferation and GM-CSF-induced gene transcription. Immunobiology, 197(1), 97–109.PubMedCrossRef
24.
Du, Y., Cullum, I., Illidge, T. M., & Ell, P. J. (2007). Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Journal of Clinical Oncology, 25(23), 3440–3447.PubMedCrossRef
25.
Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., et al. (1996). Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. The Journal of Clinical Investigation, 98(7), 1544–1549.PubMedPubMedCentralCrossRef
26.
Bendre, M. S., Margulies, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., et al. (2005). Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Research, 65(23), 11001–11009.PubMedCrossRef
27.
Bendre, M. S., Montague, D. C., Peery, T., Akel, N. S., Gaddy, D., & Suva, L. J. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 33(1), 28–37.PubMedCrossRef
28.
Aldridge, S. E., Lennard, T. W., Williams, J. R., & Birch, M. A. (2005). Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. British Journal of Cancer, 92(8), 1531–1537.PubMedPubMedCentralCrossRef
29.
Kelly, T., Suva, L. J., Nicks, K. M., MacLeod, V., & Sanderson, R. D. (2010). Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. Journal of Bone and Mineral Research, 25(6), 1295–1304.PubMedPubMedCentralCrossRef
30.
Kelly, T., Suva, L. J., Huang, Y., Macleod, V., Miao, H. Q., Walker, R. C., et al. (2005). Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Research, 65(13), 5778–5784.PubMedCrossRef
31.
Park, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., et al. (2007). NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine, 13(1), 62–69.PubMedCrossRef
32.
Chen, Y. C., Sosnoski, D. M., & Mastro, A. M. (2010). Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Research, 12(6), 215.PubMedPubMedCentralCrossRef
33.
Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714.PubMedPubMedCentralCrossRef
34.
Sethi, N., Dai, X., Winter, C. G., & Kang, Y. (2011). Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 19(2), 192–205.PubMedPubMedCentralCrossRef
35.
Ceci, F., Castellucci, P., Graziani, T., Schiavina, R., Chondrogiannis, S., Bonfiglioli, R., et al. (2015). 11C- choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clinical Nuclear Medicine, 40(5), e265–e270.PubMedCrossRef
36.
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., et al. (1995). Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine, 1(9), 944–949.PubMedCrossRef
37.
Hall, C. L., Bafico, A., Dai, J., Aaronson, S. A., & Keller, E. T. (2005). Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research, 65(17), 7554–7560.PubMed
38.
Dai, J., Hall, C. L., Escara-Wilke, J., Mizokami, A., Keller, J. M., & Keller, E. T. (2008). Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Research, 68(14), 5785–5794.PubMedPubMedCentralCrossRef
39.
Rabbani, S. A., Desjardins, J., Bell, A. W., Banville, D., Mazar, A., Henkin, J., et al. (1990). An amino- terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast- like cells. Biochemical and Biophysical Research Communications, 173(3), 1058–1064.PubMedCrossRef
40.
Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L. G., Brodt, P., Goltzman, D., et al. (1994). Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Research, 54(9), 2372–2377.PubMed
41.
Feeley, B. T., Gamradt, S. C., Hsu, W. K., Liu, N., Krenek, L., Robbins, P., et al. (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. Journal of Bone and Mineral Research, 20(12), 2189–2199.PubMedCrossRef
42.
Nishimori, H., Ehata, S., Suzuki, H. I., Katsuno, Y., & Miyazono, K. (2012). Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. The Journal of Biological Chemistry, 287(24), 20037–20046.PubMedPubMedCentralCrossRef
43.
Valta, M. P., Hentunen, T., Qu, Q., Valve, E. M., Harjula, A., Seppänen, J. A., et al. (2006). Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology, 147(5), 2171–2182.PubMedCrossRef
44.
Liao, J., Li, X., Koh, A. J., Berry, J. E., Thudi, N., Rosol, T. J., et al. (2008). Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. International Journal of Cancer, 123(10), 2267–2278.PubMedPubMedCentralCrossRef
45.
Zhang, J., Dai, J., Qi, Y., Lin, D. L., Smith, P., Strayhorn, C., et al. (2001). Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. Journal of Clinical Investigation, 107(10), 1235–1244.PubMedPubMedCentralCrossRef
46.
Corey, E., Brown, L. G., Kiefer, J. A., Quinn, J. E., Pitts, T. E., Blair, J. M., et al. (2005). Osteoprotegerin in prostate cancer bone metastasis. Cancer Research, 65(5), 1710–1718.PubMedCrossRef
47.
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., et al. (2012). Denosumab and bone- metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 379(9810), 39–46.PubMedCrossRef
48.
Jin, J. K., Dayyani, F., & Gallick, G. E. (2011). Steps in prostate cancer progression that lead to bone metastasis. International Journal of Cancer, 128(11), 2545–2561.PubMedPubMedCentralCrossRef
49.
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., et al. (2005). MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 7(5), 485–496.PubMedCrossRef
50.
Lehr, J. E., & Pienta, K. J. (1998). Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. Journal of the National Cancer Institute, 90(2), 118–123.PubMedCrossRef
51.
Glinskii, O. V., Huxley, V. H., Glinsky, G. V., Pienta, K. J., Raz, A., & Glinsky, V. V. (2005). Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia, 7(5), 522–527.PubMedPubMedCentralCrossRef
52.
Glinskii, O. V., Sud, S., Mossine, V. V., Mawhinney, T. P., Anthony, D. C., Glinsky, G. V., et al. (2012). Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia, 14(1), 65–73.PubMedPubMedCentralCrossRef
53.
Rubio, R., Gutierrez-Aranda, I., Sáez-Castillo, A. I., Labarga, A., Rosu-Myles, M., Gonzalez-Garcia, S., et al. (2013). The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene, 32(41), 4970–4980.PubMedCrossRef
54.
Kinpara, K., Mogi, M., Kuzushima, M., & Togari, A. (2000). Osteoclast differentiation factor in human osteosarcoma cell line. Journal of Immunoassay, 21(4), 327–340.PubMedCrossRef
55.
Miyamoto, N., Higuchi, Y., Mori, K., Ito, M., Tsurudome, M., Nishio, M., et al. (2002). Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. International Immunopharmacology, 2(1), 25–38.PubMedCrossRef
56.
Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., et al. (2000). Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Journal of Bone and Mineral Research, 15(9), 1766–1775.PubMedCrossRef
57.
Avnet, S., Longhi, A., Salerno, M., Halleen, J. M., Perut, F., Granchi, D., et al. (2008). Increased osteoclast activity is associated with aggressiveness of osteosarcoma. International Journal of Oncology, 33(6), 1231–1238.PubMed
58.
Urist, M. R., Nakata, N., Felser, J. M., Nogami, H., Hanamura, H., Miki, T., et al. (1977). An osteosarcoma cell and matrix retained morphogen for normal bone formation. Clinical Orthopaedics and Related Research, 124, 251–266.PubMed
59.
Zhou, X., Jing, J., Peng, J., Mao, W., Zheng, Y., Wang, D., et al. (2014). Expression and clinical significance of galectin-3 in osteosarcoma. Gene, 546(2), 403–407.PubMedCrossRef
60.
Park, G. B., Kim, D. J., Kim, Y. S., Lee, H. K., Kim, C. W., & Hur, D. Y. (2015). Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents. International Journal of Oncology, 46(1), 185–194.PubMed
61.
Lei, P., He, H., Hu, Y., & Liao, Z. (2015). Small interfering RNA-induced silencing of galectin-3 inhibits the malignant phenotypes of osteosarcoma in vitro. Molecular Medicine Reports, 12(4), 6316–6322.PubMed
62.
Mercer, N., Ahmed, H., McCarthy, A. D., Etcheverry, S. B., Vasta, G. R., & Cortizo, A. M. (2004). AGE- R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Molecular and Cellular Biology, 266(1-2), 17–24.
63.
Choi, S. J., Oba, Y., Gazitt, Y., Alsina, M., Cruz, J., Anderson, J., et al. (2001). Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. Journal of Clinical Investigation, 108(12), 1833–1841.PubMedPubMedCentralCrossRef
64.
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., et al. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine, 349(26), 2483–2494.PubMedCrossRef
65.
Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. J. (2007). Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109(5), 2106–2111.PubMedPubMedCentralCrossRef
66.
Ehrlich, L. A., Chung, H. Y., Ghobrial, I., Choi, S. J., Morandi, F., Colla, S., et al. (2005). IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106(4), 1407–1414.PubMedCrossRef
67.
Chauhan, D., Li, G., Podar, K., Hideshima, T., Neri, P., He, D., et al. (2005). A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Research, 65(18), 8350–8358.PubMedCrossRef
68.
Streetly, M. J., Maharaj, L., Joel, S., Schey, S. A., Gribben, J. G., & Cotter, F. E. (2010). GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood, 115(19), 3939–3948.PubMedCrossRef
69.
Jimi, E., Furuta, H., Matsuo, K., Tominaga, K., Takahashi, T., & Nakanishi, O. (2011). The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Diseases, 17(5), 462–468.PubMedCrossRef
70.
Zhang, X., Junior, C. R., Liu, M., Li, F., D’Silva, N. J., & Kirkwood, K. L. (2013). Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncology, 49(2), 119–128.PubMedCrossRef
71.
Carter, R. L., Tsao, S. W., Burman, J. F., Pittam, M. R., Clifford, P., & Shaw, H. J. (1983). Patterns and mechanisms of bone invasion by squamous carcinomas of the head and neck. American Journal of Surgery, 146(4), 451–455.PubMedCrossRef
72.
Shibahara, T., Nomura, T., Cui, N. H., & Noma, H. (2005). A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 34(7), 789–793.PubMedCrossRef
73.
Tada, T., Jimi, E., Okamoto, M., Ozeki, S., & Okabe, K. (2005). Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. International Journal of Cancer, 116(2), 253–262.PubMedCrossRef
74.
Okamoto, M., Hiura, K., Ohe, G., Ohba, Y., Terai, K., Oshikawa, T., et al. (2000). Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer, 89(9), 1966–1975.PubMedCrossRef
75.
Takayama, Y., Mori, T., Nomura, T., Shibahara, T., & Sakamoto, M. (2010). Parathyroid-related protein plays a critical role in bone invasion by oral squamous cell carcinoma. International Journal of Oncology, 36(6), 1387–1394.PubMed
76.
Tang, C. H., Chuang, J. Y., Fong, Y. C., Maa, M. C., Way, T. D., & Hung, C. H. (2008). Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis, 29(8), 483–492.CrossRef
77.
Pandruvada, S. N., Yuvaraj, S., Liu, X., Sundaram, K., Shanmugarajan, S., Ries, W. L., et al. (2010). Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. International Journal of Cancer, 126(10), 2319–2329.PubMedPubMedCentral
78.
Gillenwater, A., Xu, X. C., El-Naggar, A. K., Clayman, G. L., & Lotan, R. (1996). Expression of galectins in head and neck squamous cell carcinoma. Head & Neck, 18(5), 422–432.CrossRef
79.
Hossaka, T. A., Ribeiro, D. A., Focchi, G., André, S., Fernandes, M., Lopes Carapeto, F. C., et al. (2014). Expression of Galectins 1, 3 and 9 in normal oral epithelium, oral squamous papilloma, and oral squamous cell carcinoma. Dental Research Journal, 11(4), 508–512.PubMedPubMedCentral
80.
Aggarwal, S., Sharma, S. C., & Das, S. N. (2015). Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clinica Chimica Acta, 442, 13–21.CrossRef
81.
Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., et al. (2000). Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. Journal of Bone and Mineral Research, 15(4), 640–649.PubMedCrossRef
82.
Baud’huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., et al. (2010). Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. The Journal of Pathology, 221(1), 77–86.PubMedCrossRef
83.
Skubitz, K. M., Cheng, E. Y., Clohisy, D. R., Thompson, R. C., & Skubitz, A. P. (2004). Gene expression in giant-cell tumors. The Journal of Laboratory and Clinical Medicine, 144(4), 193–200.PubMedCrossRef
84.
Smink, J. J., Tunn, P. U., & Leutz, A. (2012). Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis. Journal of Molecular Medicine (Berl), 90(1), 25–30.CrossRef
85.
Japanese Society of Medical Oncology. Comprehensive guidelines on the diagnosis and treatment of bone metastases [in Japanese] (2015).
86.
Coleman, R. E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20 Pt 2), 6243s–6249s.PubMedCrossRef
87.
Gralow, J. R., Sybil Biermann, J., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., et al. (2013). NCCN Task Force Report: bone health in cancer care. Journal of the National Comprehensive Cancer Network, 11(3), S1–S51.PubMed
88.
Coleman, R., Body, J. J., Aapro, M., Hadji, P., Herrstedt, J., & Group., E. G. W. (2014). Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 25(3), 124–137.
89.
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813–822.PubMedPubMedCentralCrossRef
90.
Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., et al. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology, 28(35), 5132–5139.PubMedCrossRef
91.
Scagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., et al. (2012). Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. Journal of Thoracic Oncology, 7(12), 1823–1829.PubMedCrossRef
92.
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., et al. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29(9), 1125–1132.PubMedCrossRef
93.
Saad, F., & Eastham, J. A. (2010). Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Seminars in Oncology, Suppl 1, S38–S44.CrossRef
94.
Orita, Y., Sugitani, I., Toda, K., Manabe, J., & Fujimoto, Y. (2011). Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Thyroid, 21(1), 31–35.PubMedCrossRef
95.
Santini, D., Pantano, F., Riccardi, F., Di Costanzo, G. G., Addeo, R., Guida, F. M., et al. (2014). Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. PloS One, 9(8), e105268.PubMedPubMedCentralCrossRef
96.
Silvestris, N., Pantano, F., Ibrahim, T., Gamucci, T., De Vita, F., Di Palma, T., et al. (2013). Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PloS One, 8(10), e74402.PubMedPubMedCentralCrossRef
97.
Santini, D., Tampellini, M., Vincenzi, B., Ibrahim, T., Ortega, C., Virzi, V., et al. (2012). Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 23(8), 2072–2077.PubMedCrossRef
98.
Balan, V., Nangia-Makker, P., Schwartz, A. G., Jung, Y. S., Tait, L., Hogan, V., et al. (2008). Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Research, 68(24), 10045–10050.PubMedPubMedCentralCrossRef
Metadata
Title
Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management
Authors
Kosei Nakajima
Dong Hyo Kho
Takashi Yanagawa
Melissa Zimel
Elisabeth Heath
Victor Hogan
Avraham Raz
Publication date
01-06-2016
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2016
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-016-9622-4

Other articles of this Issue 2/2016

Cancer and Metastasis Reviews 2/2016 Go to the issue

Clinical

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

Non-Thematic Review

The promising alliance of anti-cancer electrochemotherapy with immunotherapy

NON-THEMATIC REVIEW

Deciphering the function of non-coding RNAs in prostate cancer

NON-THEMATIC REVIEW

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

NON-THEMATIC REVIEW

The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma

Clinical

miR clusters target cellular functional complexes by defining their degree of regulatory freedom
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits